12:00 AM
 | 
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

FT1050: Preliminary Phase Ib data

Preliminary data from an open-label, U.S. Phase Ib trial in 15 evaluable patients with hematologic malignancies who have undergone non-myeloablative conditioning therapy showed that dual umbilical cord blood transplantation with hematopoietic stem cells treated ex vivo with FT1050 had a similar safety profile to that of a standard double umbilical cord blood transplant. In 6 evaluable patients who received an umbilical...

Read the full 281 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >